Interleukin 8 and cardiovascular disease.
Since the establishment of the inflammatory basis of atherosclerosis, several pro- or anti-inflammatory agents have been examined as potential mediators of the biochemical pathways of lesion formation. Interleukin (IL)-8 was first characterized in 1987. Since then, knowledge regarding its role in leucocyte trafficking and activation has advanced rapidly, especially in the field of cardiovascular disease. In the scientific literature, there is sufficient evidence to support beyond any doubt the involvement of IL-8 in the establishment and preservation of the inflammatory micro-environment of the insulted vascular wall. However, how the information derived from in vitro studies and animal models can be applied in clinical practice has yet to be determined. In the present review, the available evidence regarding the role of IL-8 in cardiovascular disease is presented, and future perspectives are discussed.
Apostolakis
Stavros
S
Laboratory of Clinical Virology, Faculty of Medicine, University of Crete, 71409 Heraklion, Crete, Greece.
Vogiatzi
Konstantina
K
Amanatidou
Virginia
V
Spandidos
Demetrios A
DA
D000818:Animals; D050197:Atherosclerosis / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000378:metabolism*; D018925:Chemokines / Q000378:metabolism; D004195:Disease Models, Animal; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism*
D015415:Biomarkers; D018925:Chemokines; D016209:Interleukin-8